CPHI Americas 2026: Where Strategic Partnerships, AI, and Advanced Manufacturing Are Shaping Pharma’s Future

1. What makes CPHI Americas 2026 different from previous editions and traditional pharma trade shows?

CPHI Americas 2026 marks a fundamental shift in what a pharmaceutical industry event can be. We've moved toward a content-first experience that prioritises strategic learning and meaningful connections.

The most visible difference is our structure around five curated content tracks - US Insights, R&D Excellence focusing on Biologics, US Manufacturing Excellence, Supply Chain/AI/Emerging Technologies, and Market Strategy. Each track features industry-leading speakers addressing the specific challenges pharmaceutical professionals are grappling with right now, from regulatory uncertainty to advanced therapy manufacturing to digital transformation.

This direction reflects what our community told us they needed: deeper insights, expert perspectives, and opportunities to engage with peers facing similar challenges.

2. Why was a stronger focus placed on the CDMO and contract manufacturing ecosystem this year?

The CDMO sector has evolved from a tactical outsourcing option to a strategic imperative for pharmaceutical innovation, and several converging trends have made this focus essential for CPHI Americas 2026.

First, the economics of pharmaceutical development have fundamentally changed. More companies are adopting asset-light strategies, choosing to partner with specialised CDMOs rather than building internal manufacturing capacity for every modality and molecule. This is particularly true for advanced therapies, where the specialised expertise and capital investment required make CDMO partnerships almost inevitable.

Second, the complexity of modern therapeutics - particularly cell and gene therapies - demands manufacturing capabilities that few companies can develop internally. CDMOs have become innovation partners, not just service providers, bringing process development expertise, regulatory knowledge, and manufacturing technology that's critical to bringing new therapies to patients.

Third, capacity constraints across the industry have made CDMO relationships more strategic. Companies need to think differently about these partnerships, moving from transactional, project-based relationships to longer-term strategic alliances. Our session "Rethinking CDMO Partnerships: From Transactions to Strategy" featuring experts from Cambrex, PLD Pharma Services, and AltaSciences directly addresses this evolution. By placing CDMOs at the center of our programming, we're acknowledging their central role in the pharmaceutical ecosystem and creating the platform for the partnerships that will define the industry's future.
 
3. What are the biggest industry themes expected to dominate discussions at the event?

Several interconnected themes will drive conversations throughout CPHI Americas 2026, and they're all deeply connected to each other in interesting ways.

Regulatory uncertainty and adaptation is top of mind for everyone. The FDA is undergoing significant changes, and companies need to understand how these shifts impact their development and commercialisation strategies. Our panel "FDA in Flux: Navigating the New Regulatory Landscape", featuring Molly Klote of Klote Medical Research Advisors, will help attendees navigate this evolving environment.

Advanced therapy manufacturing is at an inflection point. The industry is moving from boutique production to scalable manufacturing while maintaining quality and personalisation. Sessions like our fireside chat with John Tomtishen, Catalent's Global Head of Cell Therapy, will explore how to unlock broader patient access to these transformative treatments.

Supply chain resilience and digital transformation have become inseparable topics. Recent disruptions have forced a fundamental rethinking of supply chain architecture. Our programming explores both immediate risk mitigation and longer-term strategies around regionalisation, and digital technologies for visibility and predictive analytics.

AI and emerging technologies are moving from experimental to operational across drug development, manufacturing, and supply chain management. We're examining practical implementation, not just theoretical potential, because that's where the industry is right now.

And of course, the evolution of CDMO relationships from transactional to strategic represents a fundamental shift in how pharmaceutical innovation happens. These themes are deeply interconnected – regulatory changes impact manufacturing strategies, supply chain resilience requires digital technologies, and advanced therapies demand new partnership models.

4. How will the event help attendees build meaningful business connections and partnerships?

We've built CPHI Americas 2026 specifically to facilitate substantive relationship building, and we've been very intentional about how we've designed every aspect of the event.

Our curated sessions bring together people with shared interests and challenges. When you attend a session on CDMO partnerships or advanced therapy manufacturing, you're surrounded by peers facing similar issues – creating natural conversation starters and the foundation for meaningful professional relationships. The content itself becomes a catalyst for connection.

Beyond traditional networking receptions, we've designed structured opportunities for connection, including our "Hot Seat" discussion sessions where small groups can engage directly with industry experts in intimate, interactive formats. Our event app enables relevant connections based on attendees' profiles, interests, and business objectives, helping people identify the right connections rather than relying on chance encounters alone.

We've also created physical environments designed for conversation – comfortable seating areas, zones for one-on-one discussions, and collaborative spaces where groups can work through ideas together. And importantly, the relationships that begin at CPHI Americas don't end when the event does. Our event app will remain live after the show to enable ongoing connection and conversation, helping transform brief in-person meetings into lasting professional relationships.

The key difference from traditional trade shows is intentionality.  CPHI Americas 2026 is designed to facilitate the kind of deep, trust-based relationships that lead to meaningful business partnerships.

5. How are AI-powered networking and matchmaking tools improving the attendee experience?

Our AI-powered networking app addresses one of the biggest challenges pharmaceutical professionals face at industry events: identifying the right people to meet among hundreds or thousands of attendees. It's something we heard about repeatedly in our feedback.

The technology analyses your connections and makes similar suggestions of other attendee profiles - including company information, role, areas of expertise, business objectives, and stated interests - to generate intelligent connection recommendations. Rather than randomly approaching people or relying solely on existing networks, attendees receive curated suggestions for connections that align with their specific goals.

 The tools also help with meeting scheduling, allowing attendees and exhibitors to request meetings and coordinate logistics through the app – eliminating the back-and-forth that often prevents connections from happening.

Importantly, these tools augment rather than replace human interaction. They handle the logistical heavy lifting and initial matching, freeing attendees to focus on the substantive conversations that build relationships. The technology creates efficiency and relevance, but the actual relationship building still happens through genuine human connection.

6. What can attendees expect from the “Hot Seat” discussion sessions?

The "Hot Seat" sessions represent an innovative format designed to break down the gap that can exist between industry experts and attendees in traditional conference settings, and I'm particularly excited to see the outcome of this session.

 The Hot Seat session is intended to be an intimate, interactive discussion.  The expert takes the "hot seat," fielding questions, sharing experiences, and engaging in real-time problem-solving with participants. We encourage authentic dialogue about the challenges, strategies, and lessons learned from real-world experience.

This format creates several unique benefits. First, attendees can ask the specific questions most relevant to their situations. Second, the small group size enables everyone to participate, creating a collaborative learning environment. Finally, the informal setting encourages candid discussion – experts can share nuanced perspectives and even acknowledge uncertainties in ways that formal presentations don't always allow.

 We want attendees to leave with practical insights they can apply immediately and often with direct connections to the experts and peers they've engaged with.

7. How is CPHI Americas addressing trends such as AI, automation, and smart manufacturing?

AI, automation, and smart manufacturing are woven throughout our content agenda because they're fundamentally transforming every aspect of pharmaceutical development and production. We're not treating these as separate topics – they're integrated into the conversations happening across all our tracks.

Our dedicated Supply Chain, AI & Emerging Technologies track explores practical implementation across the value chain. We're moving beyond theoretical discussions of AI's potential to examine real-world applications, such as how companies are using machine learning for predictive maintenance, AI for quality control and deviation investigation, and automation for process optimisation.

Sessions like "Digital Supply Chains: Navigating Risk in an Era of Intelligent Transformation" examine how digital technologies enable supply chain visibility, risk prediction, and resilient network design. We're addressing both the opportunities and the challenges - including data integration, validation requirements, and workforce adaptation.

In our Manufacturing Excellence track, we're exploring how automation and smart manufacturing technologies are changing production paradigms - from continuous manufacturing to real-time release testing to digital twins for process optimisation. But critically, we're also addressing the strategic questions these technologies raise: What's the right pace of adoption? How do you build internal capabilities versus partnering with technology providers? How do you validate AI-driven decisions in a regulated environment? What does workforce development look like when automation changes job requirements?

The goal is to help attendees understand not just what these technologies can do, but how to successfully implement them in their specific organisational contexts.

8. In what ways will sustainability and supply chain resilience be reflected across the event agenda?

Sustainability and supply chain resilience are no longer separate concerns. They're deeply interconnected strategic imperatives that appear throughout our programming, and I think that's one of the most important shifts we're seeing in the industry.

In our Supply Chain track, we're examining how companies are building resilience through diversification, regionalisation, and digital visibility while simultaneously reducing environmental impact. Sessions explore sustainable sourcing strategies, circular economy principles in pharmaceutical manufacturing, and how to balance resilience with efficiency and sustainability.

Our Manufacturing Excellence track addresses sustainable manufacturing practices - energy efficiency, waste reduction, water conservation, and green chemistry principles. We're exploring how process innovation can simultaneously improve sustainability and manufacturing economics, which is really the sweet spot everyone's looking for.

The regulatory discussions also touch on sustainability, as environmental considerations increasingly influence approval processes and market access, particularly in Europe and increasingly in other markets. We're also addressing the business case for sustainability - how environmental performance impacts brand reputation, investor relations, and talent attraction. This isn't just about compliance or corporate social responsibility; it's about competitive advantage and long-term viability.

The conversations acknowledge the tensions that exist - between resilience and efficiency, between sustainability and cost, between speed to market and environmental impact - and explore how leading companies are navigating these trade-offs.

9. How does the event cater to both large pharmaceutical companies and emerging biotech innovators?

CPHI Americas 2026 is designed to serve the entire pharmaceutical ecosystem, recognising that large pharma companies and emerging biotech innovators face both shared challenges and distinct needs, and that diversity is actually one of our greatest strengths.

Many of our sessions address universal challenges - regulatory navigation, manufacturing quality, supply chain resilience, technology adoption - that are relevant regardless of company size. The fundamental science and regulatory requirements don't change based on organisational scale. But within sessions, we ensure diverse perspectives. Panel discussions include voices from both established pharmaceutical companies and emerging biotechs, acknowledging that implementation strategies differ based on resources, organisational maturity, and risk tolerance.

For emerging biotechs, CPHI Americas is particularly valuable for identifying potential partners - CDMOs for manufacturing, technology providers for digital infrastructure, and potential acquirers or investors. Our networking tools help smaller companies connect with the right partners efficiently. Large pharma attendees often seek strategic insights about industry evolution, portfolio management, and organisational transformation, while emerging biotech innovators may need more tactical guidance about specific challenges like selecting a CDMO, navigating first regulatory submissions, or scaling manufacturing. Our diverse programming addresses both needs.

The presence of investors and private equity firms creates opportunities for emerging companies to connect with potential funding sources, while large pharma companies can identify acquisition targets and partnership opportunities. The diversity of our attendee base creates a rich ecosystem where different perspectives, capabilities, and needs come together to drive innovation and partnership.

10. What role do investors and private equity firms play within the CPHI Americas ecosystem?

Investors and private equity firms have an increasingly important role to play in the CPHI Americas ecosystem, due to the growing role of financial capital in pharmaceutical innovation.

For investors, CPHI Americas provides efficient access to emerging companies, technologies, and market trends. They can meet multiple potential portfolio companies and start-up market exhibitors, conduct informal due diligence, and understand the competitive landscape in a concentrated time. Our content programming helps investors understand the technical, regulatory, and commercial dynamics shaping pharmaceutical manufacturing and development. This context is essential for making informed investment decisions and adding value to portfolio companies.

Investors can also connect with CDMOs, technology providers, and service companies that their portfolio companies may need to partner with. These relationships enable them to facilitate introductions and support portfolio company growth. For private equity firms with pharmaceutical manufacturing or service company investments, CPHI Americas provides access to potential acquirers and opportunities to showcase portfolio companies to strategic buyers.

The concentration of industry expertise at CPHI Americas helps investors identify emerging trends, understand technology adoption curves, and assess market opportunities before they become obvious. For pharmaceutical companies, the presence of investors creates opportunities for funding, partnership, and eventual exit. For the broader ecosystem, financial capital enables innovation, capacity expansion, and technology development that might not otherwise be possible.

The integration of financial and operational perspectives enriches the conversations at CPHI Americas and reflects the reality that pharmaceutical innovation increasingly depends on effective collaboration between scientific, operational, and financial expertise. We look forward to growing the number of investors and private equity firms that attend our show as it continues to evolve to suit the changing needs of the market.

11. How important is collaboration between pharma companies, CDMOs, regulators, and technology providers today?

Collaboration across the pharmaceutical ecosystem isn't just important – it's absolutely essential for addressing the complexity of modern drug development and manufacturing.

Today's therapeutics, particularly advanced therapies, are too complex for any single organisation to develop and manufacture in isolation. Cell and gene therapies require specialised manufacturing capabilities, novel analytical methods, complex supply chains, and evolving regulatory frameworks. Success requires deep collaboration between innovators, manufacturing partners, technology providers, and regulators.

Regulatory frameworks are adapting to novel modalities and manufacturing approaches, but this evolution requires dialogue. When regulators understand the practical challenges of manufacturing and the capabilities of new technologies, they can develop frameworks that protect patients while enabling innovation. Sessions like "FDA in Flux" create space for these important conversations.

Digital technologies, automation, and AI are transforming pharmaceutical manufacturing, but successful implementation requires collaboration between pharmaceutical companies that understand the regulatory and quality requirements and technology providers who understand the capabilities and limitations of their solutions. As we've discussed, CDMOs are becoming strategic partners rather than service providers. This requires transparency, shared risk-taking, and collaborative problem-solving that goes far beyond traditional vendor relationships.

Building resilient supply chains requires coordination across multiple organisations -  raw material suppliers, manufacturers, logistics providers, and customers. CPHI Americas 2026 is designed to facilitate these collaborations by bringing diverse stakeholders together, creating forums for dialogue, and building the relationships that enable effective partnership. The pharmaceutical industry's ability to deliver innovative therapies to patients depends on how well we collaborate across organisational and functional boundaries.

12. Beyond conference sessions and exhibitions, what networking experiences can attendees look forward to?

We've designed CPHI Americas 2026 to offer diverse networking opportunities that accommodate different preferences and objectives, because we know that not everyone networks the same way.

Our opening evening reception provides a relaxed environment for initial connections, reconnecting with colleagues, and getting oriented to the event.

Rather than generic coffee breaks, we've created themed networking sessions aligned with our content tracks. If you're interested in advanced therapies, you can attend a networking break where you're surrounded by others with that same interest, which makes starting conversations so much easier.

We're also offering intimate roundtables, small-group discussions on specific topics that allow for deeper conversation than large networking events permit. These facilitated sessions bring together 8-12 people with shared interests for focused dialogue. We've created comfortable, professional spaces specifically designed for scheduled one-on-one meetings, with technology support for presentations and note-taking.

Beyond the formal program, we're facilitating informal gatherings such as our Game On! Play and Connect Hub - a high-energy networking area that fuses connection with fun in a sports-inspired environment.

Our event app enables networking before, during, and after the physical event. Attendees can start conversations before arriving in Philadelphia and continue them long after returning home.

We've also intentionally designed traffic flow, seating arrangements, and common spaces to maximise the likelihood of unexpected but valuable encounters. The variety ensures that whether you're an extrovert who thrives in large social settings or prefer smaller, more focused interactions, you'll find networking opportunities that work for you.

13. What key opportunities should first-time attendees expect from CPHI Americas 2026?

First-time attendees at CPHI Americas 2026 should come prepared to immerse themselves in the pharmaceutical industry's most important conversations and to build relationships that can shape their careers and organisations.

Our five content tracks provide a structured way to understand the current state and future direction of pharmaceutical manufacturing, development, and commercialisation. First-timers can gain perspective on how different pieces of the industry fit together. Where else can you engage directly with leaders from companies like Bayer, Catalent, Cambrex, and dozens of other industry-leading organisations? The accessibility of expertise at CPHI Americas is remarkable.

Some of the most valuable insights come from peers facing similar challenges. First-time attendees often find that conversations with people in similar roles at other companies provide practical guidance that's immediately applicable. Whether you're looking for CDMO partners, technology providers, service companies, or potential collaborators, CPHI Americas concentrates relevant organisations and decision-makers in one place.

My advice for first-timers: Come with clear objectives but remain open to unexpected opportunities. Review the agenda in advance and plan your schedule, but leave room for serendipity. Engage actively - ask questions in sessions, introduce yourself to speakers, and initiate conversations. The value you derive from CPHI Americas is directly proportional to your level of engagement.

14. Looking ahead, how do you see CPHI Americas shaping future conversations in pharmaceutical manufacturing and outsourcing?

CPHI Americas is positioned to play a catalytic role in several critical industry conversations that will define the future of pharmaceutical manufacturing and outsourcing, and I'm genuinely excited about the impact we can have.

We're helping shift the industry conversation from transactional outsourcing to strategic partnership when it comes to CDMOs.

By bringing together pharmaceutical companies, technology providers, and implementation experts, we're accelerating the adoption of AI, automation, and digital technologies. The practical insights shared at CPHI Americas help companies move from experimentation to implementation more quickly and successfully.

The manufacturing, regulatory, and commercial challenges facing cell and gene therapies require collective problem-solving. CPHI Americas creates a forum where these challenges are addressed collaboratively, helping the industry move these transformative therapies from niche applications to broader patient access.

The conversations happening at CPHI Americas about supply chain resilience and sustainability are shaping industry best practices. As companies share experiences and strategies, we're collectively developing more sophisticated approaches to these interconnected challenges.

Ultimately, CPHI Americas 2026 is more than an event - it's a platform for the conversations, relationships, and collaborations that will determine how effectively our industry delivers innovative therapies to patients. I invite everyone in the pharmaceutical community to join us in Philadelphia this June 2-4 to be part of shaping that future. Find out more about CPHI Americas and how to register for the event here.